PCV13 (Pneumococcal Conjugate) Vaccine
Recommendations, Scenarios and Q&As for healthcare professionals about PCV13 for adults
Recommendations for Adults with no Previous Pneumococcal Vaccinations
The Advisory Committee on Immunization Practices (ACIP) recommends that all adults 65 years of age or older receive a dose of PCV13 followed by a dose of PPSV23 at least 1 year later. PCV13 and PPSV23 should not be administered on the same day. ACIP also recommends that adults 19 years of age or older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first followed by a dose of PPSV23 at least 8 weeks later (see Table 1 below). Subsequent doses of PPSV23 should follow current PPSV23 recommendations for high risk adults. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19 through 64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. A second dose of PPSV23 is not recommended for persons 19 through 64 years of age with cochlear implants or CSF leaks. Additionally, those who received one or more doses of PPSV23 before age 65 years for any indication should receive one final dose of the vaccine at age 65 years or older if at least 5 years have elapsed since their previous PPSV23 dose.
Recommendations for Adults with Previous Pneumococcal Polysaccharide Vaccinations (PPSV23)
Adults 65 years of age or older who have not previously received PCV13 and who have previously received one or more doses of PPSV23 should receive a dose of PCV13. The dose of PCV13 should be given at least 1 year after receipt of the most recent PPSV23 dose.
Adults 19 years of age or older with the aforementioned conditions (functional or anatomic asplenia, immunocompromising conditions, or those with CSF leaks or cochlear implants) who have previously received one or more doses of PPSV23 should be given a dose of PCV13 one or more years after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years since the most recent dose of PPSV23.
Table 1: Medical conditions or other indications for administration of PCV13, and indications for PPSV23 administration and revaccination for adults 19 years of age or older
|Risk Group||Underlying Medical Condition||PCV13||PPSV23*|
|Recommended||Recommended||Revaccination at 5 years after first dose|
|Immunocompetent persons||Chronic heart disease†||✓|
|Chronic lung disease§||✓|
|Chronic liver disease||✓|
|Persons with functional or anatomic asplenia||Sickle cell disease/other hemoglobinopathies||✓||✓||✓|
|Congenital or acquired asplenia||✓||✓||✓|
|Immunocompromised persons||Congenital or acquired immunodeficiencies¶||✓||✓||✓|
|Chronic renal failure||✓||✓||✓|
|Solid organ transplant||✓||✓||✓|
- *All adults 65 years of age or older should receive a dose of PPSV23, regardless of previous history of vaccination with pneumococcal vaccine
- †Including congestive heart failure and cardiomyopathies
- §Including chronic obstructive pulmonary disease, emphysema, and asthma
- ¶Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease)
- ‡Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy
Scenario 1: A 24 year old sees his doctor for a routine office visit. He has asthma and has not previously received any pneumococcal vaccines. Administer vaccines as follows:
- 1 dose of PPSV23 now, at age 24
- 1 dose of PCV13 at age 65 followed by a dose of PPSV23 at least 1 year later
Note: Asthma is not an indication for adult administration of PCV13 unless the patient has received long-term systemic corticosteroids. This adult has an indication to receive a single dose of PPSV23 now. A dose of PCV13 would be given at age 65 years or older followed by a dose of PPSV23.
Scenario 2: A 28 year old woman with HIV infection received one dose of PPSV23 one year ago. Administer vaccines as follows:
- 1 dose of PCV13 now because one year has passed since receipt of PPSV23
- A second dose of PPSV23 at age 32 (if it’s been ≥5 years since previous PPSV23 and ≥8 weeks since PCV13 dose
- A third dose of PPSV23 at age 65
Scenario 3: A 42 year old man with cochlear implants who has not previously received any pneumococcal vaccines. Administer vaccines as follows:
- 1 dose of PCV13 now, at age 42
- 1 dose of PPSV23 at least 8 weeks after the dose of PCV13
- A second dose of PPSV23 at age 65
Scenario 4: A 66 year old man with chronic heart disease who received a dose of PPSV23 at age 55. Administer vaccines as follows:
- 1 dose of PCV13 now because age ≥65 and at least one year has passed since receipt of PPSV23
- 1 dose of PPSV23 at least 1 year later (and it’s been ≥5 years since previous PPSV23)
How did the Advisory Committee on Immunization Practices (ACIP) make the decision to recommend PCV13 for adults?
The evidence for PCV13 vaccination of adults 19 years or older with immunocompromising conditions and all adults 65 years or older was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. ACIP considered available studies to inform their decision-making regarding recommending PCV13 for all adults 65 years or older and those 19 or older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants.
Can PPSV23 and PCV13 be administered at the same office visit?
No. If PCV13 is indicated, administer it if at least 1 year has passed since the previous dose of PPSV23 or if no doses of PPSV23 have previously been received. Then wait at least 8 weeks for adults with immune compromise and at least 1 year for all other adults to administer PPSV23.
If an adult who is 19 through 64 years of age has already gotten one or more doses of PPSV23, when should they get PCV13, if indicated?
If indicated, PCV13 should be administered at least 1 year after the previous dose of PPSV23 was received. For those who require additional doses of PPSV23, the first such dose should be given at least 8 weeks after PCV13 and at least 5 years since the most recent dose of PPSV23.
If an adult who is 65 years of age has already gotten one dose of PCV13 before age 65 for one of the indications, should another dose of PCV13 be given at age 65?
No. If a dose of PCV13 was already received before age 65 for one of the indications, no additional PCV13 doses are needed. A dose of PPSV23 should be administered at age 65 and at least 1 year following the PCV13 dose.
Should the dose of PCV13 be repeated if given less than 1 year after a dose of PPSV23? If yes, what is the interval between doses?
No, ACIP does not recommend repeating any doses, if inadvertently administered sooner than the recommended interval. The two vaccines should never be given during the same visit.
If I inadvertently administer PPSV23 less than 8 weeks after PCV13, do I need to repeat the dose of either vaccine?
No, you do not need to repeat any doses. PPSV23 that follows PCV13 at less than 8 weeks may increase risk for localized reaction at the injection site, but remains a valid vaccination and should not be repeated. The PCV13 dose also remains valid and should not be repeated. PPSV23 and PCV13 should not be administered during the same visit.
How many doses of PPSV23 can an adult get in a lifetime? Who/when?
Some adults may be recommended to receive up to 3 doses of PPSV23 in a lifetime. Two doses of PPSV23, given 5 years apart, are indicated for adults with functional or anatomic asplenia and immunocompromising conditions before age 65 years. Those adults should then receive a third dose of PPSV23 at or after 65 years, as long as it's been at least 5 years since the previous dose.
How many doses of PCV13 can an adult get in a lifetime? Who/when?
All adults are recommended to receive 1 dose of PCV13 in a lifetime. If they received a dose of PCV13 prior to turning 65 years of age (due to a medical indication), they are not recommended an additional dose of PCV13 as part of the routine recommendation to administer PCV13 to all adults 65 years of age or older.
An adult (19 years) at high risk for IPD received a dose of PCV13 at 18 years 11 months of age. This is their only dose – no previous doses of PCV13. Does this dose count as the single dose indicated for at risk adults? If so, does the age of vaccination matter? Would the dose(s) count even if given at younger ages?
This dose would count as a single dose of PCV13 indicated for those within high risk groups. The dose of PCV13 would still count if given at younger ages.Top of Page
- Page last reviewed: September 3, 2015
- Page last updated: September 3, 2015
- Content source: